Cargando…
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
PURPOSE: Amyloid PET tracers have been developed for in vivo detection of brain fibrillar amyloid deposition in Alzheimer’s disease (AD). To serve as an early biomarker in AD the amyloid PET tracers need to be analysed in multicentre clinical studies. METHODS: In this study 238 [(11)C]Pittsburgh com...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510420/ https://www.ncbi.nlm.nih.gov/pubmed/22961445 http://dx.doi.org/10.1007/s00259-012-2237-2 |
_version_ | 1782251464601632768 |
---|---|
author | Nordberg, Agneta Carter, Stephen F. Rinne, Juha Drzezga, Alexander Brooks, David J. Vandenberghe, Rik Perani, Daniela Forsberg, Anton Långström, Bengt Scheinin, Noora Karrasch, Mira Någren, Kjell Grimmer, Timo Miederer, Isabelle Edison, Paul Okello, Aren Van Laere, Koen Nelissen, Natalie Vandenbulcke, Mathieu Garibotto, Valentina Almkvist, Ove Kalbe, Elke Hinz, Rainer Herholz, Karl |
author_facet | Nordberg, Agneta Carter, Stephen F. Rinne, Juha Drzezga, Alexander Brooks, David J. Vandenberghe, Rik Perani, Daniela Forsberg, Anton Långström, Bengt Scheinin, Noora Karrasch, Mira Någren, Kjell Grimmer, Timo Miederer, Isabelle Edison, Paul Okello, Aren Van Laere, Koen Nelissen, Natalie Vandenbulcke, Mathieu Garibotto, Valentina Almkvist, Ove Kalbe, Elke Hinz, Rainer Herholz, Karl |
author_sort | Nordberg, Agneta |
collection | PubMed |
description | PURPOSE: Amyloid PET tracers have been developed for in vivo detection of brain fibrillar amyloid deposition in Alzheimer’s disease (AD). To serve as an early biomarker in AD the amyloid PET tracers need to be analysed in multicentre clinical studies. METHODS: In this study 238 [(11)C]Pittsburgh compound-B (PIB) datasets from five different European centres were pooled. Of these 238 datasets, 18 were excluded, leaving [(11)C]PIB datasets from 97 patients with clinically diagnosed AD (mean age 69 ± 8 years), 72 patients with mild cognitive impairment (MCI; mean age 67.5 ± 8 years) and 51 healthy controls (mean age 67.4 ± 6 years) available for analysis. Of the MCI patients, 64 were longitudinally followed for 28 ± 15 months. Most participants (175 out of 220) were also tested for apolipoprotein E (ApoE) genotype. RESULTS: [(11)C]PIB retention in the neocortical and subcortical brain regions was significantly higher in AD patients than in age-matched controls. Intermediate [(11)C]PIB retention was observed in MCI patients, with a bimodal distribution (64 % MCI PIB-positive and 36 % MCI PIB-negative), which was significantly different the pattern in both the AD patients and controls. Higher [(11)C]PIB retention was observed in MCI ApoE ε4 carriers compared to non-ApoE ε4 carriers (p < 0.005). Of the MCI PIB-positive patients, 67 % had converted to AD at follow-up while none of the MCI PIB-negative patients converted. CONCLUSION: This study demonstrated the robustness of [(11)C]PIB PET as a marker of neocortical fibrillar amyloid deposition in brain when assessed in a multicentre setting. MCI PIB-positive patients showed more severe memory impairment than MCI PIB-negative patients and progressed to AD at an estimated rate of 25 % per year. None of the MCI PIB-negative patients converted to AD, and thus PIB negativity had a 100 % negative predictive value for progression to AD. This supports the notion that PIB-positive scans in MCI patients are an indicator of prodromal AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-012-2237-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3510420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-35104202012-11-30 A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease Nordberg, Agneta Carter, Stephen F. Rinne, Juha Drzezga, Alexander Brooks, David J. Vandenberghe, Rik Perani, Daniela Forsberg, Anton Långström, Bengt Scheinin, Noora Karrasch, Mira Någren, Kjell Grimmer, Timo Miederer, Isabelle Edison, Paul Okello, Aren Van Laere, Koen Nelissen, Natalie Vandenbulcke, Mathieu Garibotto, Valentina Almkvist, Ove Kalbe, Elke Hinz, Rainer Herholz, Karl Eur J Nucl Med Mol Imaging Original Article PURPOSE: Amyloid PET tracers have been developed for in vivo detection of brain fibrillar amyloid deposition in Alzheimer’s disease (AD). To serve as an early biomarker in AD the amyloid PET tracers need to be analysed in multicentre clinical studies. METHODS: In this study 238 [(11)C]Pittsburgh compound-B (PIB) datasets from five different European centres were pooled. Of these 238 datasets, 18 were excluded, leaving [(11)C]PIB datasets from 97 patients with clinically diagnosed AD (mean age 69 ± 8 years), 72 patients with mild cognitive impairment (MCI; mean age 67.5 ± 8 years) and 51 healthy controls (mean age 67.4 ± 6 years) available for analysis. Of the MCI patients, 64 were longitudinally followed for 28 ± 15 months. Most participants (175 out of 220) were also tested for apolipoprotein E (ApoE) genotype. RESULTS: [(11)C]PIB retention in the neocortical and subcortical brain regions was significantly higher in AD patients than in age-matched controls. Intermediate [(11)C]PIB retention was observed in MCI patients, with a bimodal distribution (64 % MCI PIB-positive and 36 % MCI PIB-negative), which was significantly different the pattern in both the AD patients and controls. Higher [(11)C]PIB retention was observed in MCI ApoE ε4 carriers compared to non-ApoE ε4 carriers (p < 0.005). Of the MCI PIB-positive patients, 67 % had converted to AD at follow-up while none of the MCI PIB-negative patients converted. CONCLUSION: This study demonstrated the robustness of [(11)C]PIB PET as a marker of neocortical fibrillar amyloid deposition in brain when assessed in a multicentre setting. MCI PIB-positive patients showed more severe memory impairment than MCI PIB-negative patients and progressed to AD at an estimated rate of 25 % per year. None of the MCI PIB-negative patients converted to AD, and thus PIB negativity had a 100 % negative predictive value for progression to AD. This supports the notion that PIB-positive scans in MCI patients are an indicator of prodromal AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-012-2237-2) contains supplementary material, which is available to authorized users. Springer-Verlag 2012-09-08 2013 /pmc/articles/PMC3510420/ /pubmed/22961445 http://dx.doi.org/10.1007/s00259-012-2237-2 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Nordberg, Agneta Carter, Stephen F. Rinne, Juha Drzezga, Alexander Brooks, David J. Vandenberghe, Rik Perani, Daniela Forsberg, Anton Långström, Bengt Scheinin, Noora Karrasch, Mira Någren, Kjell Grimmer, Timo Miederer, Isabelle Edison, Paul Okello, Aren Van Laere, Koen Nelissen, Natalie Vandenbulcke, Mathieu Garibotto, Valentina Almkvist, Ove Kalbe, Elke Hinz, Rainer Herholz, Karl A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease |
title | A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease |
title_full | A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease |
title_fullStr | A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease |
title_full_unstemmed | A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease |
title_short | A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease |
title_sort | european multicentre pet study of fibrillar amyloid in alzheimer’s disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510420/ https://www.ncbi.nlm.nih.gov/pubmed/22961445 http://dx.doi.org/10.1007/s00259-012-2237-2 |
work_keys_str_mv | AT nordbergagneta aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT carterstephenf aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT rinnejuha aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT drzezgaalexander aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT brooksdavidj aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT vandenbergherik aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT peranidaniela aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT forsberganton aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT langstrombengt aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT scheininnoora aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT karraschmira aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT nagrenkjell aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT grimmertimo aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT miedererisabelle aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT edisonpaul aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT okelloaren aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT vanlaerekoen aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT nelissennatalie aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT vandenbulckemathieu aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT garibottovalentina aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT almkvistove aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT kalbeelke aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT hinzrainer aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT herholzkarl aeuropeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT nordbergagneta europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT carterstephenf europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT rinnejuha europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT drzezgaalexander europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT brooksdavidj europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT vandenbergherik europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT peranidaniela europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT forsberganton europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT langstrombengt europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT scheininnoora europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT karraschmira europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT nagrenkjell europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT grimmertimo europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT miedererisabelle europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT edisonpaul europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT okelloaren europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT vanlaerekoen europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT nelissennatalie europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT vandenbulckemathieu europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT garibottovalentina europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT almkvistove europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT kalbeelke europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT hinzrainer europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease AT herholzkarl europeanmulticentrepetstudyoffibrillaramyloidinalzheimersdisease |